WO2009123348A1 - ウイルス濃縮法 - Google Patents
ウイルス濃縮法 Download PDFInfo
- Publication number
- WO2009123348A1 WO2009123348A1 PCT/JP2009/057040 JP2009057040W WO2009123348A1 WO 2009123348 A1 WO2009123348 A1 WO 2009123348A1 JP 2009057040 W JP2009057040 W JP 2009057040W WO 2009123348 A1 WO2009123348 A1 WO 2009123348A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- lectin
- carrier
- sugar
- eluate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16051—Methods of production or purification of viral material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/36—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Actinomyces; from Streptomyces (G)
Definitions
- the present invention relates to a new method for concentrating a virus or a virus vector while maintaining its infectivity, and a kit for performing the method.
- the present invention relates to a safe and simple concentration technique for vectors useful for gene therapy and vaccines such as retrovirus vector 1 and herpes virus vector 1.
- An example of a method for increasing the concentration of virus in the solution and concentrating the virus is an ultracentrifugation method.
- this method requires expensive equipment and long separation time, and requires a lot of labor for the work.
- these methods are used in subsequent procedures such as other components used in the reagent are harmful to the sensitized cells. May interfere. For this reason, the sample must be purified after virus precipitation, which requires a lot of labor.
- a method for concentrating virus particles themselves using an antibody has been developed (specialized 200 0 7 8 4 8 5). However, this method may affect the virus infectivity by inhibiting the protein function of the virus surface. For example, when separating virus particles from antibodies, it was necessary to use strong acidic conditions (for example, pH 2-3), which could cause defects in virus particles.
- virus concentration method for example, magnetic particles bound with mannose-binding lectin Is disclosed (Japanese Patent Laid-Open No. 2002-16559 Do)
- a method using streptavidin and a pyotinylated lectin is also disclosed as a method for increasing the retrovirus titer or isolating a retrovirus from a specimen sample (W02001 / 079456).
- the virus is used while bound to the carrier, and the virus itself cannot be isolated. Therefore, the usage of the virus concentrated by these methods was determined by P.
- Patent Document 1 Japanese Patent Application Laid-Open No. 2002-078485
- Patent Document 2 Japanese Patent Application Laid-Open No. 2002-165591
- Patent Document 3 International Application Publication No. WO 2001/079456 Pamphlet
- an object of the present invention is to provide a technique for concentrating virus vectors useful for gene therapy and vaccines such as a retrovirus vector and a herpesvirus vector safely and powerfully and simply.
- the present inventors have conducted a research and developed a technique capable of concentrating a virus virus vector in a solution by a simple method. More specifically, the present inventors bound a lectin to a desired virus-containing solution, further bound a virus-lectin complex with a carrier, and then separated and recovered the carrier bound with the virus, By adding, only the target virus is removed from the carrier into an appropriate amount of solution without losing infectivity. Elution and successful preparation to a concentration higher than that of the original virus-containing solution.
- the present inventors have also identified as lectins, SBA (derived from dies, sugar chains to be bound: sugar chains containing N-acetyl galactosamine (Ga 1 NAc)), S SA (two Derived from honnitoco, sugar chain to be bound: ⁇ 2-6-linked sialic acid (Siaa2-6) -containing sugar chain), DSA (derived from datura, bound sugar chain: N-acetylcylcosamine (Gl cNAc ), WGA (derived from wheat germ, bound sugar chain: N-acetyl darcosamine (GlcNAc) or sugar chain containing sialic acid), the recovery rate of virus vector is remarkable. I found it to be high.
- the present inventors succeeded in eluting the viral vector from the viral vector-binding carrier by treating the carrier to which the virus or viral vector recovered by the above method is bound with an appropriate sugar. .
- the virus isolated in this way remained infectious.
- the present inventors have proposed that as a sugar for eluting such viruses and virus vectors, chito-oligosaccharides when lectin power ⁇ WGA, N-acetylyl D-galactosamine when lectin is SBA, or It has been found that it is preferable to use a sugar containing this.
- the present invention provides a novel concentration method that enables virus and virus vectors to be easily concentrated while maintaining infectivity.
- the present invention is as follows.
- Aspect 1 Method for concentrating virus comprising the following steps:
- the lectin is linked to a molecule that can bind to the carrier, and further, by binding to the carrier via the molecule, the virus bound to the lectin indirectly binds to the carrier, or (ii) The lectin is directly bound to the carrier, so that the virus bound to the lectin binds to the carrier;
- the recovered carrier is treated with an eluate containing sugar to elute the virus from the carrier, where The eluate is smaller than the volume of the virus-containing solution in (1); and (4) The carrier is separated from the eluate in (3) to obtain a virus concentrate;
- Aspect 2 Method for concentrating virus comprising the following steps:
- Embodiment 3 The method according to embodiment 1 or 2, wherein the virus is an enveloped virus or a virus derived from the virus.
- Embodiment 4 The method according to embodiment 1 or 2, wherein the virus is a lentivirus or a herpes virus.
- the lectin is a sugar containing at least one of N-acetyl galactosamine (Ga 1 NAc;), ⁇ 2_6-linked sialic acid (Sia 2-6), and N-acetyl darcosamine (G 1 cNAc).
- a method according to embodiment 1 or 2 which is a lectin that binds.
- Aspect 6 The method according to aspect 5, wherein the lectin is selected from the group consisting of SBA (derived from soybean), SSA (derived from Nihontoko), DSA (derived from Chiyosen morning glory), and “WGA (derived from wheat germ). .
- SBA derived from soybean
- SSA derived from Nihontoko
- DSA derived from Chiyosen morning glory
- WGA derived from wheat germ
- Aspect 7 Lectin power ⁇ WGA (from wheat germ) and the sugar used for virus elution is chitooligosaccharide; or the lectin is SBA (from soybean) and the sugar used for virus elution is N-acetyl
- Virus is lentivirus, lectin power SWGA (from wheat germ), and sugar used for elution of virus is chitooligosaccharide; or virus is lentivirus
- the lectin is SBA (derived from soybean)
- the sugar used for elution of the virus is N-acetyl-D-galactosamine or a sugar containing the same;
- Embodiment 9 Method for concentrating virus comprising the following steps:
- Figure 1 is a fluorescence micrograph showing the results of testing for nonspecific adsorption of HHV-6 to tamavidin beads.
- the green dot indicates that the EGFP recombinant HH V-6 is infected with MT-4 cells, one of the Indike cells, and one dot represents one infectious virus particle ( The difference in brightness at each point is due to the difference in viral gene expression after infection. is there).
- the photo on the left shows the case where HHV-6 virus solution (stock solution) was allowed to act on MT-4 cells.
- the photo on the right shows the case where HHV-6 virus solution (stock solution) was contacted with evening mavidin beads in the absence of lectin, and the virus adsorbed on tamavidin beads was allowed to act on MT-4 cells.
- FIG. 2 is a fluorescence photomicrograph showing the results of testing the concentration effect of HHV-6 by each lectin of ABA, DSA, Lotus, MAM, and PHA_E4.
- a green dot indicates that EGFP recombinant HH V-6 is infecting MT-4 cells, which are indigenous cells, and one dot represents one infectious virus particle. (Differences in brightness at each point are due to differences in viral gene expression after infection).
- FIG. 3 is a fluorescence micrograph showing the results of testing the concentration effect of HH V-6 by lectins of P HA—L 4, UEA_I, S B A, and S S A.
- the green light points indicate that EGFP recombinant HH V-6 is infected with MT-4 cells, which are the cells of Indike, and one dot represents one infectious virus particle. (The difference in brightness at each point is due to the difference in viral gene expression after infection).
- Figure 4 is a graph showing the degree of concentration of HHV-6 in saliva by lectins and evening mavidin beads.
- Fig. 5 is a graph showing the degree of concentration of HHV-6 when lectin and evening mavidin beads are used to elute HHV-6 in saliva with concentrated opiate.
- Figure 6 is a fluorescence micrograph showing the results of testing the concentration of lentiviral vectors with lectins and evening mavidin beads.
- a green dot indicates that the EGFP recombinant lentiviral vector is infected with 2 9 3 cells, which are indike overnight cells, and one dot represents one infectious virus particle (each The difference in brightness of the spots is due to the difference in virus gene expression after infection).
- FIG. 7 is a graph showing the degree of concentration of lentiviral vector by lectin and evening mavidin beads.
- the present invention is a method for concentrating a virus comprising the following steps: (1) Contact the lectin with the virus-containing solution to bind the virus and the lectin, where
- the lectin is linked to a molecule that can bind to the carrier, and further, by binding to the carrier via the molecule, the virus bound to the lectin indirectly binds to the carrier, or (ii) The lectin is directly bound to the carrier, so that the virus bound to the lectin binds to the carrier;
- the method is provided.
- the virus to be concentrated in the method of the present invention is an enveloped virus or a virus vector derived from the virus.
- the virus to be concentrated is box virus, box virus-derived vector, togavirus, togavirus-derived vector, coronavirus, coronavirus-derived vector, flavivirus, flavivirus-derived vector, retrovirus, It may be selected from the group consisting of retrovirus-derived vectors, herpesviruses, and herpesvirus-derived vectors.
- the virus to be concentrated is lentivirus, lentivirus-derived vector, human herpesvirus 6 (variants A and B of human herpesvirus 6: hereinafter referred to as HHV-6), HHV —6-derived vector, human herpesvirus 7 (hereinafter referred to as HHV-7), HHV-7-derived vector, cytomegalovirus ( ⁇ named human herpesvirus 5), HHV-5-derived vector, Epsyutine 'Bar' virus (EBV) or EBV-derived vector, more preferably lentivirus, lentivirus-derived vector, HHV-6, HHV-6-derived vector, HHV-7 or HHV-7-derived vector May be.
- human herpesvirus 6 variant A and B of human herpesvirus 6: hereinafter referred to as HHV-6
- HHV-7 human herpesvirus 7
- HHV-7-derived vector cytomegalovirus
- cytomegalovirus ⁇ named human herpesvirus 5
- the “virus-containing liquid” means a target to be concentrated in the method of the present invention. It is a material containing virus. Therefore, the virus-containing solution may contain, for example, a virus or virus vector to be concentrated in a buffer solution, or may be a body fluid. In the present specification, the “virus-containing liquid” may be simply referred to as a sample. A solution containing the virus or virus vector to be concentrated can be prepared by a method known to those skilled in the art.
- the sickle may be selected from the group consisting of, but not limited to, saliva, blood, serum, semen, cerebral fluid, pharyngeal wiping fluid, breast milk, ascites, sweat, tears, and urine.
- Body fluids can be collected by methods known to those skilled in the art. The collected body fluid may be treated as necessary as long as it does not affect the infectivity of the virus particles.
- lectin refers to a sugar-binding protein that recognizes and binds to sugar chains.
- the sugar chain to which the lectin binds has specificity for each lectin.
- the lectin used in the method of the present invention is not particularly limited as long as it can bind to a virus.
- preferred lectins include at least one of N-acetyl galactosamine (Ga 1 NAc), ⁇ 2-6 linked sialic acid (Sia 2-6), N-acetyl darcosamine (Gl cNAc) It is a lectin that binds to a sugar chain, and more preferably SBA (dies derived lectin.
- Bound sugar chain a sugar chain containing N-acetyl galactosamine (GaNAc)), SSA (a lectin derived from two honey mint.
- Binding sugar chain ⁇ 2-6-linked sialic acid (S i aa2 -6) containing sugar chain), DSA (Datura-derived lectin.
- Linked sugar chain N-acetyl darcosamine (G 1 cNAc) containing sugar chain), or WGA (Wheat germ-derived lectin.
- Bond Sadasada N-acetylyldarcosamine (GlcNAc) or sugar chain containing sialic acid).
- SBA, SSA, DSA, or WGA can be more preferably used for concentrating human herpesvirus or human herpesvirus-derived vector.
- SBA or WGA can be more preferably used for the enrichment of lentivirus or lentivirus-derived vectors.
- the lectin may be used by directly binding to a carrier.
- the lectin may be used indirectly bound to a carrier. Indirect results An example of this is the binding of a lectin and a carrier through the binding of a piotin-piotin binding protein. More specifically, indirect binding of the lectin to the carrier is achieved by piotinizing the lectin, binding the protein to the surface of the carrier, and binding the protein to the surface of the carrier. Can be achieved.
- the carrier is not particularly limited as long as it is a solid or insoluble material (for example, a material that can be separated from the reaction mixture by filtration, soot, magnetic separation, etc.).
- Materials constituting the solid support are cellulose, Teflon (trade name), nitrocellulose, agarose, highly cross-linked spherical agarose, dextran, chitosan, polystyrene, polyacrylamide, polyester, polystrength Ponate, polyamide, polypropylene, nylon, polyvinylidene Difluoride, Latex, Silica, Glass, Glass fiber, Gold, Platinum, Silver, Copper, Iron, Stainless steel, Ferrite, Silicon wafer, Polyethylene, Polyethyleneimine, Polylactic acid, Resin, Polysaccharide, Protein (albumin etc.), Including, but not limited to, carbon or combinations thereof.
- the shape of the solid support includes beads, magnetic beads, thin films, capillaries, filters, plates, microplates, carbon nanotubes, sensor chips, etc. As is known in the art, a pit, groove, bottom of the filter, etc. may be provided.
- the magnetic peas can have a sphere diameter in the range of about 10 nm to about 1 mm. In preferred embodiments, the magnetic beads have a diameter in the range of about 25 nm to about 1 mm, about 50 nm to about 100; m. The size of the magnetic beads can be selected depending on the particular application.
- a pea comprising a highly cross-linked spherical agarose such as Sepharose can have a diameter in the range of about 24 4 im to about 1 65 m.
- the highly crosslinked spherical agarose beads have a diameter in the range of about 24 m to about 44 m.
- the size of the via-bridged spherical agarose beads can be selected depending on the particular application.
- solid supports having a hydrophobic surface examples include polystyrene latex beads such as those commercially available from Polysciences or Spherotech.
- magnetic beads with a hydrophilic surface examples include beads commercially available from Polysciences under the name B i om ag® Rupoxyl or beads from Bangs Laboratory (MC O 2 N / 2 9 2 8) Etc. Alternatively, M-270, etc. commercially available from Dynal Biotech can be used.
- the lectin and the carrier can be used by directly binding to each other.
- the carrier is a nanobead that is large enough to allow browning.
- a preferred sphere diameter range for the nanobeads is a sphere diameter of 10 nm to 100 nm, more preferably a sphere diameter of 30 nm to 70 nm.
- magnetic nanobeads such as MACS MicroBeads (diameter 50 mm) of Miltenyi Biotech Can be mentioned.
- the lectin and carrier can be linked using a protein-carrier coupling method known to those skilled in the art.
- the surface of the carrier is modified so that the carboxyl group is exposed, and the carboxyl group and the amino group of the protein are coupled in the presence of the cross-linking reagent 1-ethyl-1- (3-dimethylaminopropyl) carpositimide (EDC).
- EDC cross-linking reagent 1-ethyl-1- (3-dimethylaminopropyl) carpositimide
- the protein and the carrier can be linked.
- a carrier in which a carboxyl group on the surface of the carrier is activated esterified with N-hydroxysuccinimide (NH 2 S) and a protein are mixed in a buffer solution of PH 6.5 to 9 containing no primary amino group.
- NH 2 S N-hydroxysuccinimide
- crosslinking reagent BS 3 bis [sulfosuccinimidyl] suberate) or DSS (disuccinimidyl suberate
- SPDP N-succinimidyl 3- [2-pyridyldithio] propionate
- GMB S N- (4-maleimidobutyryloxy) succinimide
- the lectin may be used indirectly bound to a carrier.
- indirect binding of the lectin and the carrier can be achieved by piotinizing the lectin, binding the pectin-binding protein to the surface of the carrier, and binding the pectin and the thiotin-binding protein.
- beads can be preferably used as the carrier, but the preferred sphere diameter range of beads is 0.1 m to: L 00 m sphere diameter, more preferably 0.5 / m to 10 zm sphere diameter, more preferably 1 Atn! Spherical diameter of ⁇ 5 xm.
- Piotin is a general name of D — [(+) — cis-hexahydro-2-hexoxo 1H-thieno- (3,4) -imidazo-l-ru 4-valeric acid]. is there.
- Biotin is a type of water-soluble vitamin classified into the vitamin B group, sometimes called vitamin B 7 , or sometimes called vitamin H or coenzyme R. Piotin binds very strongly to avidin, a glycoprotein contained in egg white.
- the term “piotine” means iminobiot in (Hofmann, et al., (1980) Proc. Natl. Acad. Sci. USA, 77: 4666-4668), It also includes thiotin (desthiobiotin) (Hirsch, et al., (2002) Anal. Biochem., 308: 343-357), and thiotin analogues such as biocytin and biotin sulfoxide.
- a method using a piotination reagent can be mentioned.
- the PIERCE machine (linker in order is the linker, reactive group)
- EZ-Link (registered trademark) Sulfo- HS-Biotin (13.5 A, 1st grade amine)
- EZ-Link (Registered trademark) Sulfo-NHS-LC-Biotin (22.4 people, 1st grade amine)
- EZ-Link registered trademark
- EZ-Link (Registered trademark) PFP-Biotin (9.6 A, Amine)
- EZ-Link (registered trademark) Maleimide-PE0 2 -Biotin (29.1 A, thiol group), EZ-Link (registered trademark) Biotin- PE0 2 Amine (20.4A, carboxyl group), EZ-Link (registered trademark) Biotin-PE
- a piotination reagent containing NHS ester dissolve it in an organic solvent such as DMSO (dimethyl sulfoxide) or a pH 7_9 phosphate buffer, and add it to the lectin to bind it. Can do.
- an organic solvent such as DMSO (dimethyl sulfoxide) or a pH 7_9 phosphate buffer
- the carboxyl group of the lectin can be changed using a calpositimide such as EDC (1-ethyl-3- (3-dimethylaminopropyl) carpositimide hydrochloride: ⁇ ).
- EDC 1-ethyl-3- (3-dimethylaminopropyl) carpositimide hydrochloride
- a lectin to which piotin is bound may be purchased, for example, as piotin-labeled lectin from Sakai Oil Miles.
- a biotin labeling kit for example, but not limited to, EZ-Link® NHS-Lc-Biotin manufactured by Pierce, or Biot in Labeling Kit-NH2 manufactured by Dojindo Molecular Technologies) Etc.
- EZ-Link® NHS-Lc-Biotin manufactured by Pierce or Biot in Labeling Kit-NH2 manufactured by Dojindo Molecular Technologies
- the lectin gene is fused with DNA encoding a peptide containing a piotinization sequence, a vector expressing this fusion gene is constructed, and expressed as a fusion protein with the pyotinization sequence in any host ( Schwarz et al., (1988). J. Biol. Chem. 263: 9640-9645) Pyotin ⁇ lectin may be made.
- Examples of such vectors include, but are not limited to, vectors containing Invitrogen's BioEase TM tag. Among them, there are pcDNA TM 6 vector for mammalian cell expression, PET 104 vector for E. coli expression, and pM T / BioEase vector for Drosophila expression.
- the avidin-binding protein includes avidin, streptavidin, neutravidin, AVR protein (Biochem. J., (2002), 363: 609-617), bradavidin (J. Biol. Chem. , (2005), 280: 13250-13255), Rhizavidin (Biochem. J., (2007), 405: 397-405), evening mavidin and their mutants, etc. Any of them can be suitably used. In particular, tamavidin and its mutants can be preferably used.
- the evening Vidin is a piotin-binding protein discovered from the edible mushroom Pleurotus conucopiae (W0 02/072817; Takakura et al., (2009) FEBS J., 276: 1383-1397 ).
- Examples of the evening mavidin mutant include high binding ability and low non-specific binding evening mavidin (Japanese Patent Application No. 2 0 0 8-2 0 8 7 6 6 unpublished).
- “Tamavidin” in the present invention means evening mavidin 1 (amino acid sequence: SEQ ID NO: 5, nucleic acid sequence encoding it: SEQ ID NO: 4), tamavidin 2 (amino acid sequence: SEQ ID NO: 7, nucleic acid sequence encoding the same): SEQ ID NO: 6), or a variant thereof.
- the evening mavidin of the present invention typically comprises a protein comprising the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 7, or a nucleic acid comprising the base sequence of SEQ ID NO: 4 or SEQ ID NO: 6.
- the tamavidin of the present invention is a protein comprising the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 7, or a protein encoded by a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 6. It may be a protein having a piotin binding activity similar to that of Mavidin 1 or 2, or a protein having a high binding ability / low non-specific binding activity. In the present specification, evening mavidin 1, evening mavidin 2, and variants thereof may be collectively referred to simply as evening mavidin.
- a tamavidin 1 or 2 variant is a protein comprising an amino acid sequence comprising a deletion, substitution, insertion and Z or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 5 or 7, It may be a protein having a piotin binding activity similar to that of evening mavidin 1 or 2.
- the substitution may be a conservative substitution, which is the replacement of a particular amino acid residue with a residue having similar physicochemical characteristics.
- Non-limiting examples of conservative substitutions include substitution between fatty acid-containing amino acid residues, such as I 1 e, V a 1, B 61 or 8 1 a mutual substitution, Lys and A Substitutions between polar residues such as rg, G 1 u and Asp, G 1 n and Asn mutual substitution are included.
- Mutations with amino acid deletions, substitutions, insertions, and Z or addition can be performed on the DNA encoding the wild type protein, eg, site-directed mutagenesis (eg, uc leic Acid Research, Vol. 10, No. 20, p. 6487-6500, 1982, which is incorporated herein by reference in its entirety.
- site-directed mutagenesis eg, uc leic Acid Research, Vol. 10, No. 20, p. 6487-6500, 1982, which is incorporated herein by reference in its entirety.
- amino acid means an amino acid that can be deleted, substituted, inserted and / or added by site-directed mutagenesis.
- one or more amino acids may mean one or several amino acids depending on circumstances.
- Mavidin 1 or 2 variants further have at least 60%, preferably 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% with the amino acid sequence of SEQ ID NO: 5 or 7 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, more preferably 99.3% or more of a protein comprising an amino acid sequence having amino acid identity, and comprising tamavidin It may be a protein having the same piotin binding activity as 1 or 2, or a protein having a high binding ability and a low nonspecific binding activity.
- the percent identity between two amino acid sequences may be determined by visual selection and mathematical calculation. Alternatively, the percent identity between two protein sequences is based on the algorithm of Needleman, SB and Wunsch, CD (J. Mol. Biol., 48: 443-453, 1970), and the University of Wisconsin Genetics Computer Group ( It may be determined by comparing the sequence information using the GAP Review — Evening program available from UWGCG). Preferred default parameters for the GAP program include: (1) Henikoff, S. and Henikoff, JG (Proc. Natl. Acad. Sci. USA, 89: 10915-10919, 1992), Scoring 'matrix, blos um62; (2) 12 gap weights; (3) 4 gap length weights; and (4) No penalty for end gaps.
- the percent identity can be determined by comparison with sequence information using, for example, the BLAST program described in Altschul et al. (Nucl. Acids. Res., 25, p.3389-3402, 1997). .
- the program can be used online from the National Center for Biotechnology Information (Information) or the DNA Data Bank of Japan (DDBJ) website.
- the various conditions for “same search by BLAST program” 14 (parametrics) are described in detail in the same page, and it is possible to change some settings as appropriate. Do.
- the percent identity between two amino acid sequences may be determined using a program such as genetic information processing software GENETYX Ver. 7 (manufactured by Genetics) or the FASTA algorithm. The search uses the default value May be.
- the percent identity of two nucleic acid sequences can be determined by visual selection and mathematical calculation, or more preferably, this comparison is made by comparing the sequence information using a computer program.
- a typical and preferred computer program is the Wisconsin Package, Version 10.0 program “GAP” from the Genetics Convenience Group (GCG; Madison, Wis.) (Devereux, etal., 1984, Nucl. Acids Res., 12: 387).
- GAP Genetics Convenience Group
- two amino acid sequences can be compared, and a nucleic acid sequence and an amino acid sequence can be compared.
- preferable tamavidins include the following tamavidin variants. (Japanese Patent Application 2008-208766 unpublished).
- a protein showing a thiotin-binding activity comprising the amino acid sequence shown in SEQ ID NO: 7, or an amino acid sequence having 1 to several amino acid mutations in this sequence, or an amino acid sequence having 80% or more identity with this sequence .
- a modified piotin-binding protein wherein one or more residues selected from are substituted with acidic amino acid residues or neutral amino acid residues.
- the 40th aspartic acid residue is substituted with an asparagine residue, and the 104th arginine residue is substituted with a glutamic acid residue. );
- a modified vitin-binding protein (D40N—K141) in which the 40th aspartic acid residue is substituted with an asparagine residue and the 141st lysine residue is substituted with a glutamic acid residue E); and
- the 40th aspartic acid residue is substituted with an asparagine residue
- the 104th arginine residue is substituted with a glutamic acid residue
- 1 4 1st lysine residue A modified piotin-binding protein (D 4 0 N—R 1 0 4 E—K 1 4 1 E), in which the group is substituted with a dalumaate residue
- a modified piotin-binding protein selected from the group consisting of
- the linking of the piotin-binding protein and the carrier can be carried out using a force-pulling method for the protein and carrier known to those skilled in the art.
- the carrier surface is modified so that the carboxyl group is exposed, and the force lpoxyl group and the amino group of the protein are combined in the presence of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide (EDC), a cross-linking reagent.
- EDC 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide
- the protein and the carrier can be linked by force pulling reaction.
- a carrier whose carboxyl group on the surface of the carrier is activated esterified with N-hydroxysuccinimide (NH 2 S) and a protein are mixed in a buffer solution of pH 6.5 to 9 containing no primary amino group. By doing so, it is possible to bind the force lupoxyl group on the carrier surface to the amino group of the protein.
- the amino group of the carrier surface and the amino group of the protein or the crosslinking reagent SPDP (N-succinimidyl 3- [2-pyridyldithio] propionate) or GMB S (N- (4-maleimidobutyryloxy) succinimide) can be used to link the amino group on the carrier surface with the protein thiol group. it can.
- various carriers having various functional groups arranged on the surface are commercially available, and therefore they can be preferably used.
- a microplate having functional groups arranged on the surface for example, Reacti-Bind (trademark) Maleic Anhydride Activated Polystyrene 96-Well Plates (PIERCE) 1
- Immobilizer TM -Amino Modules / Plates ifi as an active amino group plate, or an ELISA plate as a carboxyl group plate, eg MS — 8 7 9 6 F (9 6 well ⁇ C type ⁇ flat bottom ' (Carbo) (Sumitomo Bakelite 3 ⁇ 4) Can be mentioned.
- microbeads having functional groups arranged on the surface as highly cross-linked agarose beads, for example, Sepharose (trademark) (GE Healthcare Biosciences) includes, but is not limited to, magnetic beads such as Dynabeads (trademark) (Dynal), and the like. For the connection, follow the instructions attached to the carrier.
- Sepharose trademark
- Dynabeads trademark
- microplates such as Reacti-Bind TM Streptavidin Coated Plates (PIERCE E3 ⁇ 4) and Nunc Streptavidin Coated 96 Micro Well TM Plates (N a 1ge Nun c3 ⁇ 4)
- commercially available magnetic beads such as Dynabeads M-280 Streptavidin (Dyna 1) and MagnaBind TM Streptavidin Beads (PI ERCE3 ⁇ 4), but are not limited thereto.
- piotin and piotin-binding protein for example, histidine tag, FLAG TM tag, or dartathione 1 S-transferase (GST) is bound to lectin, and Ni-NTA is attached to the carrier. It is also possible to indirectly bind the lectin and the carrier by binding (antibitritriacetic acid), anti-FLA G antibody, or dartathione, and binding each.
- the method of the present invention includes a step of obtaining a virus-containing liquid and a lectin.
- the conditions for bringing the virus-containing liquid into contact with the lectin are not particularly limited as long as the virus and the lectin in the virus-containing liquid are bound to each other. Elements of contact conditions include the composition of the virus-containing liquid, incubation temperature and incubation time.
- the composition of the virus-containing liquid is not particularly limited as long as the conditions for binding the virus and the lectin in the virus-containing liquid are maintained.
- a preferred virus-containing solution may be a buffer solution having a pH of 7 to 8, for example, a buffer solution based on Tris / EDTA (TE), PBS, HEPES, TBS, or the like.
- the pH of the virus-containing liquid may be 6-9, preferably 7-8. If the virus-containing liquid is a body fluid, it may be contacted with the lectin as it is or after adding a desired buffer solution or the like.
- the lower limit of the incubation temperature may be 4 or 10, and the upper limit may be 50, 45, 40, 37, 30 :, 25, and 20.
- Suitable incubation temperatures include 10 to -3 7, 10 to -25, 10 to 20, 15.
- the lower limit of the incubation time may be selected from the group consisting of 1 minute, 3 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, and the upper limit is overnight, 10 hours, 10 hours, 8 hours , 5 hours, 3 hours, 2 hours, 1.5 hours, and 1 hour.
- Preferable incubation time includes 5 minutes to 1 hour, 5 minutes to 5 hours, and 10 minutes to 2 hours.
- the lectin and the carrier are bonded via a molecule capable of binding to the carrier before, simultaneously with, or after contacting the lectin and the virus-containing solution. 3 ⁇ 4 and combine them.
- the conditions for bringing the lectin into contact with the carrier are not particularly limited as long as the lectin can sufficiently bind to the carrier via a molecule capable of binding to the carrier.
- Factors for contact conditions include incubation temperature and incubation time.
- the conditions similar to the above-mentioned conditions for contacting the virus with the lectin can be appropriately selected, but particularly preferred incubation times include 1 minute to 2 hours, 3 minutes to 1 hour, and 5 minutes to 30 minutes. .
- the carrier capturing the virus to be concentrated via the lectin is separated from the sample containing the virus and collected by a technique known to those skilled in the art according to the nature of the carrier.
- separation of the carrier from the sample may be accomplished by centrifugation followed by removal of the supernatant.
- the carrier may be separated from the sample by collecting the carrier using a magnet and removing the supernatant.
- the carrier may be separated from the sample by lifting the carrier from the sample or passing the sample through the carrier. If the carrier is designed to catch viruses inside the well structure, such as a microplate, the carrier may be separated from the sample by simply removing the sample from the Wel force.
- a step of washing the separated carrier may be added in order to remove a substance non-specifically bound to the carrier separated from the sample.
- the conditions of the washing solution and temperature used in the washing step are not particularly limited as long as the conditions of maintaining the binding between the virus and the lectin and the binding between the virus and the lectin and the carrier are maintained.
- the wash solution is buffered and may be a buffer solution having a pH of 7-8, eg, a buffer based on Tris / EDTA (TE), PBS, HEPES, TBS, etc.
- the pH of the cleaning solution may be 6-9, preferably 7-8.
- washing temperature is not particularly limited, the lower limit of the washing temperature may be 4 or 0, the upper limit is 50, 45: 40, 37, 30, 25, and 20 May be selected from the group consisting of Preferred washing temperatures include 10 to 37, 10 to 25, 1 Ot: to 20 and 15.
- the method of the present invention includes a step of eluting a virus trapped on a carrier via a lectin from the carrier using an eluate containing sugar. If the lectin and virus remain bound, it is assumed that the virus infectivity may be adversely affected depending on the type of virus. Furthermore, in concentrating viral vectors used for gene therapy, it is essential to elute and isolate viral vectors from carriers.
- elution of a virus from a carrier means that the virus trapped on the carrier is released from the carrier by dissociating the sugar chain-lectin bond to make it difficult to remove from the carrier.
- elution of a virus from a carrier means that at least a part of the virus captured by the carrier is in a state of being formed from the carrier, and all of the virus captured by the carrier is not necessarily used. Does not mean that the virus will be free.
- isolated virus in the case of elution and isolation of a virus from a carrier means that the virus trapped on the carrier is detached from the carrier and released from the carrier. And to remove the carrier component. Therefore, in the present specification, “isolated virus” means that it does not contain at least a component of a carrier, and does not necessarily define the degree of purity of the virus.
- viruses bound to a lectin can be isolated by elution from a carrier without losing the infectivity of the virus by treating with a solution containing an appropriate sugar. I found it. Therefore, in the method of the present invention, viruses bound to lectins can be eluted by using sugars. Elution of viruses from virus-binding lectins
- the sugar is selected from monosaccharides, disaccharides, oligosaccharides or glycosides having a sugar to which the lectin binds.
- sugars for elution of viruses from lectins that have captured viruses include N-acetylyl D-galactosamine for SBA, lactose for SSA, and DSA.
- WGA includes chitooligosaccharide N-acetyl-D-glucosamine.
- the eluate containing sugar is a pH 7-8 buffer, such as Tris / EDTA (TE), PBS,
- the pH of the eluate containing sugar may be 5-9, preferably 7-8.
- the concentration of sugar in the eluate containing sugar is 0.01 to: 1M, preferably 0.05M to 0.5M, more preferably 0.1M to 0.3M. Alternatively, it is 0.1% to 5% (w / v), more preferably 0.5% to 2% (w / v).
- the temperature of the elution process is not particularly limited, but the room temperature or the lower limit of the washing temperature may be 4 or 10, and the upper limit is from 50 :, 45, 40, 37, 30, 25, and 20. May be selected from the group consisting of Preferable washing temperatures include room temperature, 1 O: ⁇ 37, 10t: ⁇ 25, 10 ⁇ 20, and 15.
- the elution treatment time is not particularly limited, and may be 30 seconds to 1 day, preferably 5 minutes to 2 hours, and more preferably 1 minute to 30 minutes.
- the amount of the eluate used for elution of the virus is not particularly limited as long as it is smaller than the volume of the virus-containing solution initially used in the method of the present invention.
- it may be 1 2, 1/3, 1/4, 1/5, 1/10, 1/20, 1/50, 1/100 or 1Z500 of the original amount of virus-containing liquid.
- elution of the virus can also be achieved by making the pH of the eluate acidic (preferably pH 1-5) or alkaline (preferably pH 9-l 1). can do.
- the virus concentrate can be obtained by allowing the eluate to act on the carrier and then removing the carrier. After the treatment with the eluate, the carrier in the eluate is separated from the eluate and removed by a method known to those skilled in the art according to the nature of the carrier. For example, for particulate carriers such as beads, a virus concentrate may be obtained by centrifugation and subsequent collection of the supernatant. In the case of carrier-powered beads, the virus concentrate may be obtained by collecting the carrier using a magnet and collecting the supernatant. When the carrier is in the form of a thin film or a filter, the carrier may be separated by pulling up the carrier from the eluate or passing the sample through the carrier. If the carrier is designed to capture virus inside the well structure, such as a microplate, the virus concentrate may be obtained simply by collecting the eluate from the well.
- the present invention also provides a kit for concentrating a virus in a virus-containing liquid based on the method of the present invention.
- the kit of the present invention comprises at least a pyotinylated lectin, a carrier bound with a pyotin-binding protein, and a sugar for elution.
- Lectins, piotin-binding proteins, carriers and elution sugars are as defined above.
- the kit of the present invention comprises at least nanobeads bound with a lectin and a saccharide for elution.
- Lectins, nanobeads and sugars for elution are as defined above.
- the kit of the present invention is further used in the method of the present invention to buffer a virus and a lectin, to wash a separated virus-binding carrier, and to elute the virus from Z or the carrier. Buffer solution may be included.
- each reagent may be enclosed in a suitable container. Further, the kit of the present invention may also include a package for appropriately packing the reagents contained therein.
- the kit of the present invention may contain appropriate instructional materials. Instructions for use include, but are not limited to, instructions on how to use the package, or printed materials, electronic storage media (eg magnetic disks, tapes, cartridges, tips), and optical media (eg CD ROM), Etc., and a medium that can convey to the user how to use the kit of the present invention.
- electronic storage media eg magnetic disks, tapes, cartridges, tips
- optical media eg CD ROM
- Etc. e.g CD ROM
- Etc. e.g CD ROM
- the address description on the Internet site that provides the instruction manual is also included in the instruction manual. It is.
- HHV cultured with 15 types of pectin lectins (Con A, DBA, LCA, PHA-E4, PNA, RCA120, UEA-I, WGA, ABA, DSA, Lotus, MAM, PHA-L4, SBA, SSA) — Reacted with 6 solutions, evening magnetic binding with mavidin (whether it was possible to concentrate HH V-6 by binding to 4 beads.
- pectin lectins Con A, DBA, LCA, PHA-E4, PNA, RCA120, UEA-I, WGA, ABA, DSA, Lotus, MAM, PHA-L4, SBA, SSA
- a cultured T cell derived from umbilical cord blood was infected with recombinant HHV-6 expressing EGF P (Patent No. 39235 05) to prepare an EGFP type HHV-6 solution.
- Magnetic beads coated with carboxyl groups (Dynabeads M-270 Carboxylic, Acid, Dynal 3 ⁇ 4) 300 1 were washed with 0.01N sodium hydroxide 300 1 for 10 minutes, and then with brine 300 1 for 10 minutes. Washed 3 times per minute.
- the EG FP type HHV-6 solution prepared in 1 was placed on the shelf and it was confirmed whether virus concentration was achieved using the infectious titer of recombinant HHV-6 as an indicator.
- There are 15 types of J-Oil Mills lectins Con A, DBA, LCA, PHA-E4, PNA, RCA120, UEA-I, WGA, ABA, DSA, Lotus, MAM, PHA-L4, SBA, SSA) It was used.
- EGFP recombinant HHV-6 solution 100 1 (virus concentration 10 4 / m 1 TE) and PBS 500 1 were mixed and incubated at 15 for 1 hour (mixed by inversion).
- the evening mavidin magnetic beads prepared in 2 above were added to the reaction solution, and further incubated at 15 for 1 hour (mixed by inversion).
- the Eppendorf tube containing the reaction solution was placed on a magnetic stand for Dynabeads, and then washed twice with PBS 2 mM EDTA 0.5% BS A 200 1.
- this was suspended in a culture medium (RPMI 1640 + 10% urine fetal serum) 5001, and the entire amount was suspended with 0.5 ml of Indike overnight cells (MT 4 cells).
- EGFP-type HHV-6 is present, EGFP-type HH V-6 is infected with Lindike-Evening cells, and HHV-6 DNA enters the cell, and the EGFP gene incorporated into the virus is contained therein. It is thought to express and emit GFP fluorescence.
- both the virus with the beads still attached and the sensitized vesicle are sinking to the bottom of the liquid. Therefore, the decrease in the association probability between the virus and the infected cell, which can be a problem, is usually a problem.
- the virus concentration in the local area becomes very high, and the infection efficiency is expected to improve.
- EGFP recombinant HHV-6 solution 100 1 virus concentration 10 4 Zm 1 TE
- PBS 500 1 piotinylated lectin 1 O ⁇ g
- the evening mavidin magnetic beads prepared in 2 above were added to the reaction solution, and further incubated for 1 hour at 15 (mixed by inversion).
- Saliva from the subject was collected using salivets (salivet cotton, manufactured by Sarstatt). The subject squeezed the oral cavity twice with distilled water just before collecting saliva, and then included saliva in the oral cavity for 2 minutes and collected saliva.
- the obtained DNA was subjected to quantitative PCR.
- quantitative PCR the HHV-6 U65 / 66 region was quantified by real-time PCR.
- the primer and probe sequences used for PCR were
- TaqMan probe FAM 5 '-AGCAGCTGGCGAAAAGTGCTGTGC-3' TAMRA (SEQ ID NO: 3), using FastStart Universal Probe Master (Rox) (Roche 3 ⁇ 4) at reaction temperature 95 Real-time PCR was performed once for 10 minutes, 5 cycles of 95 seconds + 60 31 seconds, and 45 cycles.
- Saliva 400 1 collected as described in item 1 above was mixed with 10 times the concentration of PBS and piotylated SBA 1 nmo 1 and incubated at 15 for 1 hour (mixed by inversion).
- evening mavidin magnetic beads 1001 prepared in Example 1 were added to the reaction solution, and further incubated at 15 for 1 hour (inversion mixing).
- the Etpendorf tube containing the reaction solution was set on a magnet stand for Dynabeads, and then washed three times with PBS 5001. TE was added to this and treated with 98 for 10 minutes, and then the supernatant was collected on a magnet stand, 5 l of which was subjected to quantitative PCR.
- quantitative PCR the HHV-6 U65 66 region was quantified by the real-time PCR method in the same manner as in item 2 of this Example.
- the amount of HHV-6 in the eluate 51 used for quantitative PCR was measured as 2934 copies (Fig. 4).
- the HHV-6 solution could be concentrated about 40 times by using the biotinylated SBA and evening mavidin magnetic beads.
- the concentration efficiency was about 15 times.
- the amount of HHV-6 contained in the test plots without the addition of pyotinylated lectin was 40 copies or less and was not concentrated (Fig. 4).
- the elution sugar in the eluate is N-acetylyl D-galactosamine (0.2 M) in the system using piotinylated SBA, and chitooligosaccharide (1%) in the system using piotinylated WGA. It was. Then, the eluate-treated test tube containing the eluate was placed on a magnetic stand for Dynabeads, and the evening mavidin magnetic beads were collected, and the supernatant was collected. 51 of the collected liquid thus obtained was subjected to quantitative PCR. In Quantitative PCR, the HHV-6 U 65/66 region was quantified by real-time PCR as in item 2 above.
- the lentivirus used was the HI V base gene and the LSV virus vector with the VSV-G envelope recombined with the EGFP gene (provided by Dr. Hiroyuki Miyoshi of the independent administrative corporation Rika ⁇ W Laboratory) .
- Piotinylated lectins are manufactured by J—Oil Mills, Inc. 1 5 types (Con A, DBA, LCA, PHA-E4, PNA, RCA120, UEA-I, WGA, ABA, DSA, Lotus, MAM, PHA-L4, SBA, SSA) were used.
- EGFP recombinant lentivirus solution 100 ⁇ 1 virus concentration 10 2 Zm 1 TE, virus with low titer was used to observe concentration effect
- PBS 50 0 fi I piotin 1 O g of modified lectin was mixed and incubated for 1 hour at 15 (mixed by inversion).
- the evening mavidin magnetic beads prepared in Example 1 were added to the reaction solution, and further incubated for 1 hour at 15 (inversion mixing).
- the Eppendorf tube containing the reaction solution was placed on a magnetic stand for Dynabeads, and then washed twice with PBS 2 mM EDTA 0.5% BSA 200 1.
- PBS 2 mM EDTA 0.5% BSA 200 1.
- concentration rate was quantified.
- EG FP recombinant lentivirus solution (titer: 10 Vm 1)
- 200 g of pyotinylated SBA or pyotinylated WGA then add 100 ⁇ 1 tamavidin magnetic beads for 15 min at room temperature They were combined by inversion. This was placed on a magnetic stand for Dynabeads, washed twice with PBS containing 0.5% ushi serum albumin and 2 mM EDTA, and 100 1 eluate (for elution with PBS + 2% urine fetal serum). Elution with sugar added).
- the elution sugar in the eluate was N-acetyl-D-galactosamine (0.2M) for SBA and chitooligosaccharide (1%) for WGA. Thereafter, the eluate-treated test tube containing the eluate was placed on a Dynabeads magnet stand to collect tamavidin magnetic beads, and the supernatant was collected. The recovered liquid thus obtained was infected by adsorbing the virus titer to Indike overnight cells (HeLa cells) at 37 for 1 hour, and the number of EG FP-expressing cells one day later was infected. The Ilska value was measured.
- the present invention provides a novel method and kit for carrying out the method, which makes it possible to more easily concentrate viruses and virus vectors in a virus solution having a low concentration.
- the method of the present invention makes it easy to concentrate while maintaining the infectivity of viruses and virus vectors. For example, in the fields of gene therapy and vaccine therapy using virus vectors, It is expected to be used as a simple vector enrichment technique. More specifically, since the method of the present invention is a simple method that does not require complicated column operation or ultracentrifugation as in the conventional method, it can be expected to be applied to automation and high-throughput systems.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2009232598A AU2009232598A1 (en) | 2008-03-31 | 2009-03-31 | Enrichment method of virus |
CN2009801121585A CN101983238B (zh) | 2008-03-31 | 2009-03-31 | 病毒浓缩方法 |
JP2010506006A JPWO2009123348A1 (ja) | 2008-03-31 | 2009-03-31 | ウイルス濃縮法 |
US12/935,492 US20110053250A1 (en) | 2008-03-31 | 2009-03-31 | Enrichment method of virus |
CA2722957A CA2722957A1 (en) | 2008-03-31 | 2009-03-31 | Enrichment method of virus |
EP09727365A EP2267119A4 (en) | 2008-03-31 | 2009-03-31 | PROCESS FOR VIRUS ENRICHMENT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008092816 | 2008-03-31 | ||
JP2008-092816 | 2008-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009123348A1 true WO2009123348A1 (ja) | 2009-10-08 |
Family
ID=41135696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/057040 WO2009123348A1 (ja) | 2008-03-31 | 2009-03-31 | ウイルス濃縮法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110053250A1 (ja) |
EP (1) | EP2267119A4 (ja) |
JP (1) | JPWO2009123348A1 (ja) |
KR (1) | KR20100127774A (ja) |
CN (1) | CN101983238B (ja) |
AU (1) | AU2009232598A1 (ja) |
CA (1) | CA2722957A1 (ja) |
WO (1) | WO2009123348A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011045358A (ja) * | 2009-07-28 | 2011-03-10 | Kagoshima Univ | ウイルスの濃縮方法および磁性体組成物 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8304236B2 (en) * | 2008-08-13 | 2012-11-06 | Japan Tobacco Inc. | Modified biotin-binding protein |
JP5959440B2 (ja) | 2010-01-19 | 2016-08-02 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 病原体の検出および治療のための改変オプソニン |
EP2547436A2 (en) * | 2010-03-17 | 2013-01-23 | President and Fellows of Harvard College | Melt emulsification |
JP2014523914A (ja) | 2011-07-18 | 2014-09-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作された微生物標的化分子およびその使用 |
AU2013225823A1 (en) | 2012-02-29 | 2014-09-18 | President And Fellows Of Harvard College | Rapid antibiotic susceptibility testing |
CA2886769C (en) * | 2012-10-05 | 2022-01-04 | Denka Seiken Co., Ltd. | Method for measuring hemagglutinin from influenza virus |
EP2976642A4 (en) | 2013-03-15 | 2016-09-21 | Harvard College | METHODS AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR CAPTURE OF A TARGET ENTITY |
KR101548167B1 (ko) * | 2013-04-23 | 2015-09-04 | 한국기초과학지원연구원 | 노로바이러스 또는 a형 간염 바이러스 농축 및 검출방법 |
JP6649250B2 (ja) | 2013-05-21 | 2020-02-19 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたヘム結合性構成物およびその使用 |
WO2015095604A2 (en) | 2013-12-18 | 2015-06-25 | President And Fellows Of Harvard College | Methods and assays relating to circulating tumor cells |
EP3331549B1 (en) | 2015-08-06 | 2020-12-23 | President and Fellows of Harvard College | Improved microbe-binding molecules and uses thereof |
US20200400667A1 (en) * | 2019-06-21 | 2020-12-24 | Indevr, Inc. | Method for the quantification of measles and rubella targets |
JP2022539148A (ja) * | 2019-06-28 | 2022-09-07 | 武田薬品工業株式会社 | アデノ随伴ウイルスの精製方法 |
CN113980911B (zh) * | 2021-10-13 | 2023-08-22 | 天津大学 | 富集病毒的微马达的制备方法及其应用 |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD128002A1 (de) * | 1976-10-20 | 1977-10-26 | Volker Wunderlich | Verfahren zur isolierung von viren,insbesondere von rns-tumorviren |
JPH1146789A (ja) * | 1997-08-08 | 1999-02-23 | Tomita Seiyaku Kk | UDP−GalNAcの製造法 |
WO2001079456A2 (en) | 2000-04-18 | 2001-10-25 | Cancer Research Technology Limited | Materials and methods relating to increasing viral titre |
JP2002078485A (ja) | 2000-06-27 | 2002-03-19 | Jsr Corp | ウイルス濃縮用材料およびウイルス濃縮方法 |
JP2002165591A (ja) | 2000-09-25 | 2002-06-11 | Jsr Corp | 磁性粒子およびその使用方法 |
WO2002072817A1 (fr) | 2001-03-12 | 2002-09-19 | Japan Tobacco Inc. | Nouvelle proteine, gene codant ladite proteine et procede d'utilisation correspondant |
WO2004000220A2 (en) * | 2002-06-21 | 2003-12-31 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
WO2004016789A1 (ja) * | 2002-08-19 | 2004-02-26 | Sumitomo Corporation | カーゴレセプターの遺伝子改変による糖鎖ライブラリー |
JP2007024661A (ja) * | 2005-07-15 | 2007-02-01 | Niigata Univ | 糖鎖不全IgA分子の定量方法及び定量キット |
JP3923505B2 (ja) | 2003-08-29 | 2007-06-06 | 株式会社ウイルス医科学研究所 | Hhv−6由来の組換ウイルスベクター、その製造方法、それを用いた宿主細胞の形質転換方法、それにより形質転換された宿主細胞およびそれを用いた遺伝子治療方法 |
WO2008006780A1 (en) * | 2006-07-11 | 2008-01-17 | Bia Separations D.O.O. | Method for influenza virus purification |
JP2008208766A (ja) | 2007-02-26 | 2008-09-11 | Nippon Telegr & Teleph Corp <Ntt> | 回転機構一体型発電装置 |
WO2008138533A1 (en) * | 2007-05-14 | 2008-11-20 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
-
2009
- 2009-03-31 WO PCT/JP2009/057040 patent/WO2009123348A1/ja active Application Filing
- 2009-03-31 EP EP09727365A patent/EP2267119A4/en not_active Withdrawn
- 2009-03-31 KR KR1020107019850A patent/KR20100127774A/ko not_active Application Discontinuation
- 2009-03-31 AU AU2009232598A patent/AU2009232598A1/en not_active Abandoned
- 2009-03-31 JP JP2010506006A patent/JPWO2009123348A1/ja active Pending
- 2009-03-31 CA CA2722957A patent/CA2722957A1/en not_active Abandoned
- 2009-03-31 US US12/935,492 patent/US20110053250A1/en not_active Abandoned
- 2009-03-31 CN CN2009801121585A patent/CN101983238B/zh not_active Expired - Fee Related
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD128002A1 (de) * | 1976-10-20 | 1977-10-26 | Volker Wunderlich | Verfahren zur isolierung von viren,insbesondere von rns-tumorviren |
JPH1146789A (ja) * | 1997-08-08 | 1999-02-23 | Tomita Seiyaku Kk | UDP−GalNAcの製造法 |
WO2001079456A2 (en) | 2000-04-18 | 2001-10-25 | Cancer Research Technology Limited | Materials and methods relating to increasing viral titre |
JP2002078485A (ja) | 2000-06-27 | 2002-03-19 | Jsr Corp | ウイルス濃縮用材料およびウイルス濃縮方法 |
JP2002165591A (ja) | 2000-09-25 | 2002-06-11 | Jsr Corp | 磁性粒子およびその使用方法 |
WO2002072817A1 (fr) | 2001-03-12 | 2002-09-19 | Japan Tobacco Inc. | Nouvelle proteine, gene codant ladite proteine et procede d'utilisation correspondant |
WO2004000220A2 (en) * | 2002-06-21 | 2003-12-31 | Genetix Pharmaceuticals, Inc. | Methods for purifying viral particles for gene therapy |
WO2004016789A1 (ja) * | 2002-08-19 | 2004-02-26 | Sumitomo Corporation | カーゴレセプターの遺伝子改変による糖鎖ライブラリー |
JP3923505B2 (ja) | 2003-08-29 | 2007-06-06 | 株式会社ウイルス医科学研究所 | Hhv−6由来の組換ウイルスベクター、その製造方法、それを用いた宿主細胞の形質転換方法、それにより形質転換された宿主細胞およびそれを用いた遺伝子治療方法 |
JP2007024661A (ja) * | 2005-07-15 | 2007-02-01 | Niigata Univ | 糖鎖不全IgA分子の定量方法及び定量キット |
WO2008006780A1 (en) * | 2006-07-11 | 2008-01-17 | Bia Separations D.O.O. | Method for influenza virus purification |
JP2008208766A (ja) | 2007-02-26 | 2008-09-11 | Nippon Telegr & Teleph Corp <Ntt> | 回転機構一体型発電装置 |
WO2008138533A1 (en) * | 2007-05-14 | 2008-11-20 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
Non-Patent Citations (25)
Title |
---|
ALTSCHUL ET AL., NUCL. ACIDS. RES., vol. 25, 1997, pages 3389 - 3402 |
BANKS WA ET AL.: "Adsorptive endocytosis mediates the passage of HIV-1 across the blood- brain barrier: evidence for a post- internalization coreceptor", J. CELL. SCI., vol. 111, no. PT.4, 1998, pages 533 - 540, XP008143508 * |
BANKS WA ET AL.: "HIV-1 protein gp120 crosses the blood-brain barrier: role of adsorptive endocytosis", LIFE SCI., vol. 61, no. 9, 1997, pages PL119 - PL125, XP008143507 * |
BANKS WA ET AL.: "Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis", J. VIROL., vol. 75, no. 10, 2001, pages 4681 - 4691, XP008143288 * |
BIDAWID S ET AL.: "Rapid concentration and detection of hepatitis A virus from lettuce and strawberries", J. VIROL. METHODS, vol. 88, no. 2, 2000, pages 175 - 185, XP008143506 * |
BIOCHEM. J., vol. 363, 2002, pages 609 - 617 |
BIOCHEM. J., vol. 405, 2007, pages 397 - 405 |
GATELLIER P ET AL.: "The binding of N- trifluoroacetyl chito-oligosaccharides to wheat-germ agglutinin: a fluorescence investigation", BIOCHIM. BIOPHYS. ACTA., vol. 916, no. 3, 1987, pages 428 - 436, XP025448918 * |
HENIKOFF, S.; HENIKOFF, J. G., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 10919 |
HIRSCH ET AL., ANAL. BIOCHEM., vol. 308, 2002, pages 343 - 357 |
HOFMANN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4666 - 4668 |
J. BIOL. CHEM., vol. 280, 2005, pages 13250 - 13255 |
KRISTIANSEN T ET AL.: "Virus Purification by Vicia ervilia Lectin Coupled to Sepharose", PROTIDES OF THE BIOLOGICAL FLUIDS, vol. 23, 1976, pages 663 - 665, XP008143500 * |
MARCHETTI M ET AL.: "Inhibition of herpes simplex, rabies and rubella viruses by lectins with different specificities", RES. VIROL., vol. 146, no. 3, 1995, pages 211 - 215, XP008143289 * |
NEEDLEMAN, S. B.; WUNSCH, C. D., J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
NUCLEIC ACID RESEARCH, vol. 10, no. 20, 1982, pages 6487 - 6500 |
OPITZ L ET AL.: "Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses", VACCINE, vol. 25, no. 5, 15 January 2007 (2007-01-15), pages 939 - 947, XP005798885 * |
SATO K ET AL.: "Demonstration of sugar moiety on the surface of hepatitis C virions recovered from the circulation of infected humans", VIROLOGY, vol. 196, no. 1, 1993, pages 354 - 357, XP008143501 * |
SCHWARZ ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 9640 - 9645 |
See also references of EP2267119A4 * |
SHINOHARA Y ET AL.: "Elucidation of the mechanism enhancing the avidity of lectin with oligosaccharides on the solid phase surface", GLYCOBIOLOGY, vol. 7, no. 8, 1997, pages 1201 - 1208, XP008143505 * |
TAKAKURA ET AL., FEBS J., vol. 276, 2009, pages 1383 - 1397 |
TAKEOMI MURATA ET AL.: "Chito-oligosaccharide o Sokusa ni Motsu Kobunshitai no Gosei to Lectin tono Sogo Sayo", CHITIN AND CHITOSAN RESEARCH, vol. 2, no. 2, 1996, pages 100 - 101, XP008143503 * |
WITTELS M ET AL.: "Penetration of cells by herpes simplex virus does not require a low pH- dependent endocytic pathway", VIRUS RES., vol. 18, no. 2-3, 1991, pages 271 - 290, XP023896927 * |
ZIEGLER RJ ET AL.: "Effects of lectins on peripheral infections by herpes simplex virus of rat sensory neurons in culture.", INFECT. IMMUN., vol. 34, no. 2, 1981, pages 588 - 595, XP008143290 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011045358A (ja) * | 2009-07-28 | 2011-03-10 | Kagoshima Univ | ウイルスの濃縮方法および磁性体組成物 |
US9464281B2 (en) | 2009-07-28 | 2016-10-11 | SUDx-Biotec Corporation | Method for concentrating viruses, method for concentrating cells or bacteria, and magnetic composite |
Also Published As
Publication number | Publication date |
---|---|
CN101983238B (zh) | 2013-06-12 |
CN101983238A (zh) | 2011-03-02 |
US20110053250A1 (en) | 2011-03-03 |
AU2009232598A1 (en) | 2009-10-08 |
EP2267119A4 (en) | 2011-05-25 |
EP2267119A1 (en) | 2010-12-29 |
KR20100127774A (ko) | 2010-12-06 |
JPWO2009123348A1 (ja) | 2011-07-28 |
CA2722957A1 (en) | 2009-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009123348A1 (ja) | ウイルス濃縮法 | |
EP2267151A1 (en) | Virus titration method | |
JP5656339B2 (ja) | タンパク質固定化担体およびその製造方法 | |
JP5686098B2 (ja) | アビジンとビオチン誘導体の解離方法及び解離剤 | |
JP2010518046A (ja) | 病原体の結合 | |
JP4866977B2 (ja) | 抗梅毒トレポネーマ抗体測定試薬 | |
JPWO2013018836A1 (ja) | 生物学的試料中の物質を検出する工程において、非特異的結合を抑制する方法、当該方法に使用するための剤 | |
WO2018190357A1 (ja) | レクチンの固定化方法 | |
JP2014512843A (ja) | 細胞からの抽出 | |
JP2006327962A (ja) | 目的物質の分離方法および分子コンプレックス | |
WO2010001841A1 (ja) | Mdp1による微生物を凝集および/または沈殿させる方法 | |
JP7406789B2 (ja) | 細菌メンブランベシクルの単離方法、単離キット、およびその除去方法 | |
CN108362876B (zh) | 一种检测克罗诺杆菌的免疫磁珠层析试纸条及快速检测方法 | |
CN109270064B (zh) | 一种基于葡聚糖微球的免疫沉淀试剂及其制备方法与应用 | |
CN116539875A (zh) | 用于检测水痘-带状疱疹病毒感染的试剂及其制备方法 | |
CN113788880A (zh) | 一种人巨细胞病毒重组抗原的纯化方法 | |
CN116041455A (zh) | 一种高效功能性磁小体(bmp-csa) | |
JP2006042743A (ja) | 細菌の回収方法 | |
JPWO2008081938A1 (ja) | 耐熱性ビオチン結合性タンパク質の利用法、および当該タンパク質が結合した固体担体 | |
JP2010104250A (ja) | Mdp1を用いた炭水化物を有する物質の分離方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980112158.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09727365 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20107019850 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010506006 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009727365 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009232598 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2722957 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009232598 Country of ref document: AU Date of ref document: 20090331 Kind code of ref document: A |